Functional and clinical relevance of novel and known PCSK1 variants for childhood obesity and glucose metabolism

Molecular Metabolism

Volumn 6, Issue 3, 2017, Pages 295-305

  Löffler, Dennis ^a,b   Behrendt, Susanne ^a,b   Creemers, John W M ^c   Klammt, Jürgen ^a   Aust, Gabriela ^b   Stanik, Juraj ^a,d,e   Kiess, Wieland ^a   Kovacs, Peter ^b   Körner, Antje ^a,b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Physics and Informatics   (Slovakia)

^e INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Children; Obesity; PC1 3; PCSK1; Prohormone convertase 1 3

Indexed keywords

PROINSULIN; PROPROTEIN CONVERTASE 1; GLUCOSE; INSULIN; PCSK1 PROTEIN, HUMAN;

ADOLESCENT; ALLELE; ANIMAL CELL; ARTICLE; BODY MASS; CELLULAR DISTRIBUTION; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; EXON; FEMALE; GENE IDENTIFICATION; GENE LOCATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HETEROZYGOTE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; NONHUMAN; PCSK1 GENE; PHENOTYPE; PROTEIN LOCALIZATION; PROTEIN SECRETION; SANGER SEQUENCING; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; METABOLISM;

ADOLESCENT; BLOOD GLUCOSE; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; MALE; PEDIATRIC OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASE 1;

EID: 85009188337     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.12.002     Document Type: Article

References (55)

1. [1] Benzinou, M., Creemers, J.W., Choquet, H., Lobbens, S., Dina, C., Durand, E., et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nature Genetics 40 (2008), 943–945.
2. [2] Nead, K.T., Li, A., Wehner, M.R., Neupane, B., Gustafsson, S., Butterworth, A., et al. Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. Human Molecular Genetics 24 (2015), 3582–3594.
3. [3] Stijnen, P., Tuand, K., Varga, T.V., Franks, P.W., Aertgeerts, B., Creemers, J.W., The association of common variants in PCSK1 with obesity: a HuGE review and meta-analysis. American Journal of Epidemiology 180 (2014), 1051–1065.
4. [4] Strawbridge, R.J., Dupuis, J., Prokopenko, I., Barker, A., Ahlqvist, E., Rybin, D., et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 60 (2011), 2624–2634.
5. [5] Seidah, N.G., Mattei, M.G., Gaspar, L., Benjannet, S., Mbikay, M., Chretien, M., Chromosomal assignments of the genes for neuroendocrine convertase PC1 (NEC1) to human 5q15-21, neuroendocrine convertase PC2 (NEC2) to human 20p11.1-11.2, and furin (mouse 7[D1-E2] region). Genomics 11 (1991), 103–107.
6. [6] Martin, L.J., Comuzzie, A.G., Dupont, S., Vionnet, N., Dina, C., Gallina, S., et al. A quantitative trait locus influencing type 2 diabetes susceptibility maps to a region on 5q in an extended French family. Diabetes 51 (2002), 3568–3572.
7. [7] Vaughan, L.K., Wiener, H.W., Aslibekyan, S., Allison, D.B., Havel, P.J., Stanhope, K.L., et al. Linkage and association analysis of obesity traits reveals novel loci and interactions with dietary n-3 fatty acids in an Alaska Native (Yup'ik) population. Metabolism 64 (2015), 689–697.
8. [8] Barat-Houari, M., Clement, K., Vatin, V., Dina, C., Bonhomme, G., Vasseur, F., et al. Positional candidate gene analysis of Lim domain homeobox gene (Isl-1) on chromosome 5q11-q13 in a French morbidly obese population suggests indication for association with type 2 diabetes. Diabetes 51 (2002), 1640–1643.
9. [9] Ramos-Molina, B., Martin, M.G., Lindberg, I., PCSK1 variants and human obesity. Progress in Molecular Biology and Translational Science 140 (2016), 47–74.
10. [10] Stijnen, P., Ramos-Molina, B., O'Rahilly, S., Creemers, J.W., PCSK1 mutations and human endocrinopathies: from obesity to gastrointestinal disorders. Endocrine Reviews 37 (2016), 347–371.
11. [11] Farooqi, I.S., Volders, K., Stanhope, R., Heuschkel, R., White, A., Lank, E., et al. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. The Journal of Clinical Endocrinology & Metabolism 92 (2007), 3369–3373.
12. [12] Wen, W., Cho, Y.S., Zheng, W., Dorajoo, R., Kato, N., Qi, L., et al. Meta-analysis identifies common variants associated with body mass index in East Asians. Nature Genetics 44 (2012), 307–311.
13. [13] Ruiz-Narvaez, E.A., Haddad, S.A., Rosenberg, L., Palmer, J.R., Birth weight modifies the association between central nervous system gene variation and adult body mass index. Journal of Human Genetics 61 (2016), 193–198.
14. [14] Blanco, E.H., Ramos-Molina, B., Lindberg, I., Revisiting PC1/3 mutants: dominant-negative effect of endoplasmic reticulum-retained mutants. Endocrinology 156 (2015), 3625–3637.
15. [15] Mbikay, M., Sirois, F., Nkongolo, K.K., Basak, A., Chretien, M., Effects of rs6234/rs6235 and rs6232/rs6234/rs6235 PCSK1 single-nucleotide polymorphism clusters on proprotein convertase 1/3 biosynthesis and activity. Molecular Genetics and Metabolism 104 (2011), 682–687.
16. [16] Pickett, L.A., Yourshaw, M., Albornoz, V., Chen, Z., Solorzano-Vargas, R.S., Nelson, S.F., et al. Functional consequences of a novel variant of PCSK1. PLoS One, 8, 2013, e55065.
17. [17] Jackson, R.S., Creemers, J.W., Ohagi, S., Raffin-Sanson, M.L., Sanders, L., Montague, C.T., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nature Genetics 16 (1997), 303–306.
18. [18] Harter, B., Fuchs, I., Muller, T., Akbulut, U.E., Cakir, M., Janecke, A.R., Early clinical diagnosis of PC1/3 deficiency in a patient with a novel homozygous PCSK1 splice-site mutation. Journal of Pediatric Gastroenterology and Nutrition 62 (2016), 577–580.
19. [19] Frank, G.R., Fox, J., Candela, N., Jovanovic, Z., Bochukova, E., Levine, J., et al. Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. Molecular Genetics and Metabolism 110 (2013), 191–194.
20. [20] Jackson, R.S., Creemers, J.W., Farooqi, I.S., Raffin-Sanson, M.L., Varro, A., Dockray, G.J., et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. Journal of Clinical Investigation 112 (2003), 1550–1560.
21. [21] Martin, M.G., Lindberg, I., Solorzano-Vargas, R.S., Wang, J., Avitzur, Y., Bandsma, R., et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology 145 (2013), 138–148.
22. [22] Creemers, J.W., Choquet, H., Stijnen, P., Vatin, V., Pigeyre, M., Beckers, S., et al. Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes 61 (2012), 383–390.
23. [23] Philippe, J., Stijnen, P., Meyre, D., De Graeve, F., Thuillier, D., Delplanque, J., et al. A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity. International Journal of Obesity (London) 39 (2015), 295–302.
24. [24] Reich, A., Müller, G., Gelbrich, G., Deutscher, K., Godicke, R., Kiess, W., Obesity and blood pressure-results from the examination of 2365 schoolchildren in Germany. International Journal of Obesity and Related Metabolic Disorders 27 (2003), 1459–1464.
25. [25] Landgraf, K., Friebe, D., Ullrich, T., Kratzsch, J., Dittrich, K., Herberth, G., et al. Chemerin as a mediator between obesity and vascular inflammation in children. The Journal of Clinical Endocrinology & Metabolism 97 (2012), E556–E564.
26. [26] Kromeyer-Hauschild, K., Wabitsch, M., Kunze, D., Geller, F., Geiß, H.C., Hesse, V., et al. Perzentile für den Body-mass-Index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschrift Kinderheilkunde 149 (2001), 807–818.
27. [27] Rosenbloom, K.R., Armstrong, J., Barber, G.P., Casper, J., Clawson, H., Diekhans, M., et al. The UCSC genome browser database: 2015 update. Nucleic Acids Research 43 (2015), D670–D681.
28. [28] Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A., Batzoglou, S., Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Computational Biology, 6, 2010, e1001025.
29. [29] Kumar, P., Henikoff, S., Ng, P.C., Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature Protocols 4 (2009), 1073–1081.
30. [30] Choi, Y., Chan, A.P., PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 31 (2015), 2745–2747.
31. [31] Reva, B., Antipin, Y., Sander, C., Determinants of protein function revealed by combinatorial entropy optimization. Genome Biology, 8, 2007, R232.
32. [32] Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., Shendure, J., A general framework for estimating the relative pathogenicity of human genetic variants. Nature Genetics 46 (2014), 310–315.
33. [33] Capriotti, E., Calabrese, R., Fariselli, P., Martelli, P.L., Altman, R.B., Casadio, R., WS-SNPs&GO: a web server for predicting the deleterious effect of human protein variants using functional annotation. BMC Genomics, 14(Suppl. 3), 2013, S6.
34. [34] Hazel, M., Cooksey, R.C., Jones, D., Parker, G., Neidigh, J.L., Witherbee, B., et al. Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology, 2003.
35. [35] Orci, L., Tagaya, M., Amherdt, M., Perrelet, A., Donaldson, J.G., Lippincott-Schwartz, J., et al. Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. Cell 64 (1991), 1183–1195.
36. [36] Rose, A.B., Intron-mediated regulation of gene expression. Current Topics in Microbiology and Immunology 326 (2008), 277–290.
37. [37] Back, S.H., Kaufman, R.J., Endoplasmic reticulum stress and type 2 diabetes. Annual Review of Biochemistry 81 (2012), 767–793.
38. [38] Woehlbier, U., Hetz, C., Modulating stress responses by the UPRosome: a matter of life and death. Trends in Biochemical Sciences 36 (2011), 329–337.
39. [39] Ma, Y., Brewer, J.W., Diehl, J.A., Hendershot, L.M., Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. Journal of Molecular Biology 318 (2002), 1351–1365.
40. [40] Yoshida, H., Okada, T., Haze, K., Yanagi, H., Yura, T., Negishi, M., et al. Endoplasmic reticulum stress-induced formation of transcription factor complex ERSF including NF-Y (CBF) and activating transcription factors 6alpha and 6beta that activates the mammalian unfolded protein response. Molecular Cell Biology 21 (2001), 1239–1248.
41. [41] Lin, W.C., Chuang, Y.C., Chang, Y.S., Lai, M.D., Teng, Y.N., Su, I.J., et al. Endoplasmic reticulum stress stimulates p53 expression through NF-kappaB activation. PLoS One, 7, 2012, e39120.
42. [42] Walter, P., Ron, D., The unfolded protein response: from stress pathway to homeostatic regulation. Science 334 (2011), 1081–1086.
43. [43] Lin, J.H., Li, H., Yasumura, D., Cohen, H.R., Zhang, C., Panning, B., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 318 (2007), 944–949.
44. [44] Fewell, S.W., Travers, K.J., Weissman, J.S., Brodsky, J.L., The action of molecular chaperones in the early secretory pathway. Annual Review of Genetics 35 (2001), 149–191.
45. [45] Zhu, X., Zhou, A., Dey, A., Norrbom, C., Carroll, R., Zhang, C., et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proceedings of the National Academy of Sciences of the United States of America 99 (2002), 10293–10298.
46. [46] Mbikay, M., Croissandeau, G., Sirois, F., Anini, Y., Mayne, J., Seidah, N.G., et al. A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission and heterozygous female susceptibility to dietary fat. Developmental Biology 306 (2007), 584–598.
47. [47] Lloyd, D.J., Bohan, S., Gekakis, N., Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Human Molecular Genetics 15 (2006), 1884–1893.
48. [48] Heni, M., Haupt, A., Schafer, S.A., Ketterer, C., Thamer, C., Machicao, F., et al. Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion. BMC Medical Genetics, 11, 2010, 86.
49. [49] Kilpelainen, T.O., Bingham, S.A., Khaw, K.T., Wareham, N.J., Loos, R.J., Association of variants in the PCSK1 gene with obesity in the EPIC-Norfolk study. Human Molecular Genetics 18 (2009), 3496–3501.
50. [50] Qi, Q., Li, H., Loos, R.J., Liu, C., Hu, F.B., Wu, H., et al. Association of PCSK1 rs6234 with obesity and related traits in a Chinese Han population. PLoS One, 5, 2010, e10590.
51. [51] Chang, Y.C., Chiu, Y.F., Shih, K.C., Lin, M.W., Sheu, W.H., Donlon, T., et al. Common PCSK1 haplotypes are associated with obesity in the Chinese population. Obesity (Silver Spring) 18 (2010), 1404–1409.
52. [52] Jansen, E., Ayoubi, T.A., Meulemans, S.M., Van de Ven, W.J., Neuroendocrine-specific expression of the human prohormone convertase 1 gene. Hormonal regulation of transcription through distinct cAMP response elements. Journal of Biological Chemistry 270 (1995), 15391–15397.
53. [53] Shen, X., Li, Q.L., Brent, G.A., Friedman, T.C., Thyroid hormone regulation of prohormone convertase 1 (PC1): regional expression in rat brain and in vitro characterization of negative thyroid hormone response elements. Journal of molecular endocrinology 33 (2004), 21–33.
54. [54] Bianchi, M., Crinelli, R., Giacomini, E., Carloni, E., Magnani, M., A potent enhancer element in the 5′-UTR intron is crucial for transcriptional regulation of the human ubiquitin C gene. Gene 448 (2009), 88–101.
55. [55] Bennett, K.L., Romigh, T., Arab, K., Teresi, R.E., Tada, Y., Eng, C., et al. Activator protein 2 alpha (AP2alpha) suppresses 42 kDa C/CAAT enhancer binding protein alpha (p42(C/EBPalpha)) in head and neck squamous cell carcinoma. International Journal of Cancer 124 (2009), 1285–1292.